Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (TRUST)

Last updated: May 14, 2024
Sponsor: Ruijin Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Lymphoma

Non-hodgkin's Lymphoma

Treatment

84-gene penal

Clinical Study ID

NCT05934864
RJ-PTCL-3
  • Ages > 18
  • All Genders

Study Summary

A multi-center, prospective, registry study to analyze the clinical characteristics and prognosis of different molecular subtypes of peripheral T-cell lymphoma.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients diagnosed with peripheral T-cell lymphoma (PTCL) by histopathology fromJune 2023 to December 2026 and detected by gene sequencing (NGS) with differentmolecular subtypes.

  • Patients diagnosed with PTCL by histopathology from January 2023 to June 2023 andNGS detection can be performed if there is tumor tissue.

  • Informed consented

  • Age ≥ 18 years

Exclusion

Exclusion Criteria:

  • History of malignancy except for basal cell or squamous cell carcinoma of the skinor carcinoma in situ of the cervix prior to study treatment

  • Uncontrollable cardio-cerebral vascular, coagulative, autoimmune, serious infectiousdisease

  • Not able to comply to the protocol for mental or other unknown reasons

  • Patients with mentally disorders or other reasons unable to fully comply with thestudy protocol

  • Pregnant or lactation

Study Design

Total Participants: 1000
Treatment Group(s): 1
Primary Treatment: 84-gene penal
Phase:
Study Start date:
July 13, 2023
Estimated Completion Date:
June 01, 2026

Study Description

Peripheral T-cell lymphoma (PTCL）is a distinct and heterogeneous histopathologic subtype of non-Hodgkin lymphoma (NHL), accounting for ~10%. Patients with PTCL still have poor treatment response and prognosis under conventional CHOP regimen. This multi-center, prospective, registry study is designed to analyze the clinical characteristics and prognosis of different molecular subtypes of PTCL. The results can guide future precision therapy for PTCL.

Connect with a study center

  • Peking University People's Hospital

    Beijing, 100044
    China

    Active - Recruiting

  • Henan Cancer Hospital

    Henan, 450003
    China

    Active - Recruiting

  • Affiliated Drum Tower Hospital, Medical School of Nanjing University

    Nanjing, 210008
    China

    Active - Recruiting

  • Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China

    Shandong,
    China

    Site Not Available

  • Shanghai Institute of Hematology, Rui-Jin Hospital affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, 200025
    China

    Active - Recruiting

  • Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

    Sichuan,
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.